Moxetumomab provides a CD22-targeting recombinant antibody fragment for immunotoxin and oncology research. It serves as the antibody-binding component of moxetumomab pasudotox, a CD22-directed immunotoxin that incorporates a modified Pseudomonas exotoxin A payload. This research platform specifically supports studies of B-cell malignancies, targeted protein delivery, and antibody-mediated cellular recognition.
Key Features and Benefits
- CD22-Targeting Antibody Fragment: Recognizes CD22, a cell-surface glycoprotein expressed primarily on B-lineage cells.
- Recombinant Antibody Design: Uses an engineered antibody variable fragment to specifically support selective CD22 recognition.
- Immunotoxin Research Component: Provides the targeting component associated with the CD22-directed immunotoxin moxetumomab pasudotox.
- CD22 Recognition: Supports investigation of CD22 expression, antibody binding, receptor internalization, and B-cell targeting.
- Targeted Delivery Research: Enables studies of antibody-mediated delivery strategies specifically involving CD22-expressing cells.
- B-Cell Malignancy Research: Supports investigation of CD22 as a therapeutic target in hairy cell leukemia and related B-cell malignancies.
- Antibody Engineering Platform: Provides a research model specifically for studying recombinant antibody fragments and targeted immunotoxin design.
Applications
- Hairy Cell Leukemia Research: Supports investigation of CD22 expression and antibody-targeting strategies in hairy cell leukemia models.
- B-Cell Leukemia Research: Especially useful for studying CD22 recognition and cellular targeting in relevant B-cell leukemia models.
- CD22-Positive Cancer Research: Supports investigation of antibody binding and receptor-mediated internalization in CD22-expressing malignant cells.
- Immunotoxin Research: Useful for studying the targeting component of recombinant immunotoxins and antibody-directed toxin delivery.
- Antibody Engineering Research: Supports evaluation of engineered antibody fragments and antigen-recognition strategies.
- Targeted Cancer Research: Enables investigation of CD22-directed approaches for selective targeting of malignant B cells.
- Cell-Based Binding Assays: Useful for evaluating CD22-dependent antibody binding and cellular uptake.
- Mechanism-of-Action Studies: Supports investigation of CD22 recognition and receptor-mediated internalization.
- Comparative Antibody Research: Useful for comparing CD22-targeting antibody fragments, immunotoxins, and antibody-based delivery platforms.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for recombinant antibody fragments and protein research materials. Maintain conditions that preserve protein stability and antigen-binding activity.
Moxetumomab provides a recombinant CD22-targeting antibody fragment associated with the immunotoxin moxetumomab pasudotox and specifically supports hairy cell leukemia, B-cell malignancy, antibody engineering, immunotoxin, and targeted cancer research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
